Loading patent…
AssigneesMax-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
InventorsThomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
Estimating the term…
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
A method of mediating RNA interference of an mRNA in a cell or an organism, comprising:
A method of mediating RNA interference of an mRNA in a cell or an organism in which RNA interference occurs, comprising:
A method of mediating RNA interference in a cell or an organism, comprising:
Dependencies are inferred from the claim text.